JiangSu WuZhong Pharmaceutical Development is suspected of violations related to information disclosure and has been filed for investigation after years of losses, just turning a profit.|Brief Announcement
① JiangSu WuZhong Pharmaceutical Development has been put under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws; ② The company has reported a net income loss for six consecutive years, yet aims to turn a profit in 2024 by focusing on a single product in the medical aesthetics sector; ③ Previously, the company faced several instances of being penalized for various legal violations, but none have occurred in the last three years.
The photovoltaic film business is unlikely to turn a profit in the short term. Folai Ant New Energy Fund will suspend production | Quick read announcement.
① The photovoltaic film is currently facing intense price competition and a capacity adjustment period, so Fu Lai An Te new energy fund has decided to suspend production and operations to reduce losses; ② The decline in the selling price of the film products is greater than the decrease in unit costs, resulting in a further drop in the gross margin of the film products.
The launch of new medical beauty products contributed to performance, jiangsu wuzhong pharmaceutical development's net profit in the first three quarters increased by more than three times. | Interpretations
① In the first three quarters, jiangsu wuzhong pharmaceutical development's net profit attributable to the parent company increased by 311.54% year-on-year; ② The significant increase in performance during the reporting period of the AestheFill aesthetic facial filler contributed mainly to the company's performance growth; ③ The decline in the pharmaceutical sector business continues to expand.
Argus Research Initiates Coverage On Novo Nordisk With Buy Rating, Announces Price Target of $110
Argus Research Maintains Buy on Costco Wholesale, Raises Price Target to $650
Argus Research Reiterates Buy on Amazon.com, Maintains $165 Price Target